RxDoctor Payments Data

Joseph Holley

Nurse Practitioner · Huntsville, ALNPI 1184077208

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $11,971 of the $15,579 with a category attached, or 76.8%. 28 manufacturers reported payments, led by Sanofi at 28.5% of the total. 2025 is the largest year on record at $6,451, 2.5 times the $2,583 reported in 2021. Among nurse practitioner clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,579in general payments, 2019–2025

Across 705 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$4K
  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$764
  • Ardelyx, Inc.$505
  • plus $3K from 22 others

What the payments were for

  • Consulting fees$2,61617%
  • Travel & lodging$8175%
  • Food & beverage$11,97177%
  • Education$1751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,579 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$57,952
Medicare patients
386
Services billed
635

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide49$50,657
MotegrityPrucalopride Succinate16$12,004
Dexlansoprazole DrDexlansoprazole17$5,542
Omeprazole221$4,055
Mesalamine ErMesalamine22$3,990
Pantoprazole Sodium245$3,366
Colestipol Hcl38$2,922
Sucralfate41$2,797
Colesevelam Hcl14$2,308
Esomeprazole Magnesium38$1,962
Famotidine76$1,021
Dicyclomine Hcl27$851
Nadolol14$772

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,012$50,65749 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$764$12,00416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →